X
[{"orgOrder":0,"company":"Endeavor Biomedicines","sponsor":"Omega Funds","pharmaFlowCategory":"D","amount":"$62.0 million","upfrontCash":"Undisclosed","newsHeadline":"Endeavor BioMedicines Launches with $62 Million Series A Financing and Mission to Reverse the Course of Devastating Pulmonary Disease","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Endeavor Biomedicines","sponsor":"Ally Bridge Group","pharmaFlowCategory":"D","amount":"$101.0 million","upfrontCash":"Undisclosed","newsHeadline":"Endeavor BioMedicines Closes $101M Series B Financing to Advance Clinical-Stage Precision Medicine Pipeline","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Endeavor Biomedicines","sponsor":"xCures","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Endeavor BioMedicines Partners with xCures to Identify Patients with PTCH1 mutations for Phase 2 Trial of ENV-101 (taladegib)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Endeavor Biomedicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Endeavor Doses First Patient in Phase 2 Oncology Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Endeavor Biomedicines","sponsor":"AyurMaya","pharmaFlowCategory":"D","amount":"$132.5 million","upfrontCash":"Undisclosed","newsHeadline":"Endeavor BioMedicines Raises $132.5 Million Oversubscribed Series C Financing to Advance Pipeline of Transformational Medicines","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2024","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Endeavor Biomedicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Endeavor BioMedicines Completes Enrollment in Phase 2a Clinical Trial of ENV-101 (Taladegib) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"September 2023","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Endeavor Biomedicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Endeavor BioMedicines Successfully Completes Phase 2a Trial of ENV-101 in Patients with Idiopathic Pulmonary Fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2024","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Endeavor Biomedicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ENV-101 Phase 2a Shows Lung Function, Fibrosis Reversal in IPF","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II"}]
Find Clinical Drug Pipeline Developments & Deals for Taladegib
Filters
Companies By Therapeutic Area
Details:
ENV-101 (taladegib) is an oral small molecule inhibitor of the Hedgehog (Hh) signaling pathway. It is being evaluated in phase 2 clinical studies for the treatment of idiopathic pulmonary fibrosis.
Lead Product(s):
Taladegib
Therapeutic Area: Pulmonary/Respiratory Diseases
Product Name: ENV-101
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
May 19, 2024
Details:
Endeavor will use the financing proceeds to advance the clinical development of ENV-101, its lead candidate for the treatment of idiopathic pulmonary fibrosis.
Lead Product(s):
Taladegib
Therapeutic Area: Pulmonary/Respiratory Diseases
Product Name: ENV-101
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
AyurMaya
Deal Size: $132.5 million
Upfront Cash: Undisclosed
Deal Type: Series C Financing
April 24, 2024
Details:
ENV-101 (taladegib) is an oral small molecule inhibitor of the Hedgehog (Hh) signaling pathway. It is being evaluated in phase 2 clinical studies for the treatment of idiopathic pulmonary fibrosis.
Lead Product(s):
Taladegib
Therapeutic Area: Pulmonary/Respiratory Diseases
Product Name: ENV-101
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
January 24, 2024
Details:
ENV-101 (taladegib) is a small-molecule inhibitor of the Hedgehog (Hh) signaling pathway, which plays a critical role in idiopathic pulmonary fibrosis disease pathology.
Lead Product(s):
Taladegib
Therapeutic Area: Pulmonary/Respiratory Diseases
Product Name: ENV-101
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
September 06, 2023
Details:
The partnership helps identify patients whose cancers harbor the PTCH1 mutation and may be eligible for Endeavor’s clinical trial for ENV-101 (taladegib). The xCures platform also enables patients to find more suitable treatment options if they are ineligible.
Lead Product(s):
Taladegib
Therapeutic Area: Oncology
Product Name: ENV-101
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
xCures
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Partnership
May 31, 2022
Details:
ENV-101 (taladegib), an orally available small molecule inhibitor of the Hedgehog signaling pathway, has already demonstrated preliminary clinical efficacy and safety in nearly 200 subjects enrolled across six completed studies.
Lead Product(s):
Taladegib
Therapeutic Area: Oncology
Product Name: ENV-101
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
May 25, 2022
Details:
Proceeds will support the Endeavor’s pipeline, including ENV-101 (taladegib), a small molecule inhibitor of PTCH1 receptor, for the treatment of cancer and idiopathic pulmonary fibrosis and ENV-201, a small molecule inhibitor of ULK1/2 for the treatment of KRAS-driven cancers.
Lead Product(s):
Taladegib
Therapeutic Area: Pulmonary/Respiratory Diseases
Product Name: ENV-101
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Ally Bridge Group
Deal Size: $101.0 million
Upfront Cash: Undisclosed
Deal Type: Series B Financing
February 07, 2022
Details:
Proceeds from the financing will be used to advance taladegib, an inhibitor of the Hedgehog pathway, into two Phase 2 clinical studies for the treatment of idiopathic pulmonary fibrosis (IPF) in 2021.
Lead Product(s):
Taladegib
Therapeutic Area: Pulmonary/Respiratory Diseases
Product Name: ENV-101
Highest Development Status: Phase I
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Omega Funds
Deal Size: $62.0 million
Upfront Cash: Undisclosed
Deal Type: Series A Financing
January 07, 2021